Y Belkacemi (France), A Bounedjar (Algeria), J Gligorov (France),
R Samlali (Morocco), S Turkan (Turkey)
MAIN ROOM
Moderators
P Tsoutsou (Switzerland) - M AL Foheidi (SA) - H Errihani (Morocco)
14:10-14:40:
Keynote 1: Molecular classifications of BC for practice : update and upcoming
N Radosevic (France)
14:40-15:00:
Locally advanced breast cancer interactive patient case 1:
Multidisciplinary management of Triple Negative BC: neoadjuvant and adjuvant guidelines
A Awada (Belgium), E Gazioglu (Turkey), Case presentation by: K Debbi (France)
Locally advanced breast cancer interactive patient case 2:
Multidisciplinary management of Her2 positive BC: neoadjuvant and adjuvant guidelines
K El Hassani (Morocco), MP Chauvet (France), Case presentation by: M Bojovic (Serbia)
15:20-15:40:
Locally advanced breast cancer interactive patient case 3:
Multidisciplinary management of HR+/Her2- non-menopausal BC: standards and options
A Taghian (USA), G Gligorov (France), Case presentation by: B Al Qadi (SA)
15:40-16:00:
Round table discussion and take home messages for daily practice
P Tsoutsou (Switzerland), M AL- Foheidi (SA), H Errihani (Morocco)
16:00- 16:20 :
MAIN ROOM
Moderators
ER Ozlem (Turkey) - O Ivanov (Serbia) - Y Bensouda (Morocco)
Cervix interactive patient case 1:
Multidisciplinary management of stage IB-IIA cervix cancer
K Kerrou (France), M Güngor (Turkey), Case presentation by: C Atahan (Turkey)
16:40-17:00:
Cervix interactive patient case 2:
Multidisciplinary management of stage IIIB-IV cervix cancer
C Chargari (France), C Taskiran (Turkey), Case presentation by : O Nouri (Tunisia)
17:00-17:20:
Round table discussion and take home messages for daily practice
O Ivanov (Serbia), Er Ozlem (Turkey), Y Bensouda (Morocco)
17:20-17:50:
Keynote 2: Cervix cancer management: surgery and metabolic imaging for optimal staging?
K Kerrou (France)
MAIN ROOM
A Bounedjar (Algeria) - J Gligorov (France) - R Samlali (Morocco)
Arome Projects and publication strategy and Partnership (ATTICA PROJECT: Use of IT communication technologies and dATa proTection In onCology hospitAls)
J Malicki (Poland), D Tesanovic (Serbia) M. Mocydlarz-Adamcewicz (Poland)
CLOSING REMARKS
Y Belkacemi (France)
MEDITERRANEAN SCIENTIFIC SOCIETIES EXCHANGES DINNER
MAIN ROOM
Moderators
M Oukkal (Algeria) - Y Belkacemi (France) - B Atalar (Turkey)
Keynote 3: Intermediate and high risk PCa : Past and Current challenges for optimal combined radio-homonotherapy
M Bolla (France)
09:00-09:30:
Surgery for high risk PCa is a validated option?
In favor for multimodal strategy including surgery
In favor for combined radiohormonotherapy without surgery
B Argun (Turkey ), F Geara (UAE)
09:30-10:00:
Combined hormonotherapy and radiation is the standard for ALL intermediate risk PCa:
In favor
Against
D Tesanovic (Serbia), C Obek (Turkey)
10:00-10:30:
Management of oligometastatic castrate-sensitive prostate cancer (mCSPCa):
In favor to use the systemic “triplet” protocol early
In favor to standard hormonotherapy and stereotactic radiation
L Popovic (Serbia), M Krengli (Italy)
10:30:
Round table discussion and take home messages for daily practice
M Oukkal (Algeria), Y Belkacemi (France), B Atalar (Turkey)
10:45-11:00:
Coffee break
Moderators
F Geara (UAE) - D Mukherji (UAE) - A Dib (Algeria)
11:00-11:20:
Keynote 4: How to optimize local therapy in the new era of hormone therapy for synchronous mCSPCa ?
E Ozyar (Turkey)
11:20- 11:40:Interactive patient case 1: Personalizing the sequence of local and systemic therapy in mCSPCa
G Demir (Turkey), H Boussen (Tunisia), Case presentation by FZ Bellefkih (Morocco)
11:40-12:00 :
Interactive patient case 2: Role of sequential of systemic and local therapies in mCRPCa
K Oualla (Morocco), M Ozsahin (Switzerland), Case presentation by S Zaidi (Algeria)
12:00-12:20:
Keynote 5 : How to personalize in 2024 systemic therapy in mCRPCa ?
D Mukherji (UAE)
12:20-12:30:
Round table discussion and take home messages for daily practice
F Geara (UAE), D Mukherji (UAE)
12:30-13:00:by J Gligorov (France)
by K Oualla (Morocco)
Lunch break
14:00-15:30:
MAIN ROOM
Coordination:
Y Belkacemi (France), A Bounedjar (Algeria),
S Turkan (Turkey)
Report by A Awada (Belgium), J Gligorov (France)
Loco-regional treatments in cN0 and cN1 BC: Axilla management after neoadjuvant therapy ?
MP Chauvet (France), Y Bolukbasi (Turkey)
Adjuvant therapy in HR positive, HER2 negative BC : wich adjuvant systemic therapy in residual disease after neoadjuvant therapy?
N Berrada (Morocco), J Gligorov (France)
Adjuvant therapy in young women with HR positive, HER2 negative BC: type and duration of endocrine therapy?
H Boussen (Tunisia), H Errihani (Morocco), A Awada (Belgium)
Loco-regional treatments in cN0 and cN1 BC : radiation therapy volumes according to the response after neoadjuvant therapy ?
P Tsoutsou (Switzerland), A Taghian (USA)
ROOM 2
Coordination:
R Samlali (Morocco), S Kanoun (Tunisia), C Taskiran (Turkey)
Report by C Chargari (France), D Tesanovic (Serbia)
Imaging and AI for staging
G Dagoglu Kartal (Turkey)
Combined radiochemotherapy and surgery indications
C Chargari (France), M Oukkal (Algeria)
External beam radiotherapy and brachytherapy
O Ivanov (Serbia), I Flandin (France), S Sahraoui (Morocco)
Follow-up: timing, tools, duration
D Tesanovic (Serbia), ER Ozlem (Turkey), FZ Bellefkih (Morocco)
ROOM 1
L Popovic (Serbia), F Geara (UAE), F Guedea (Spain)
Report by F Geara (UAE), D Mukherji (UAE)
Local therapies in oligometastatic situations: how to optimize the sequence?
E Ozyar (Turkey), C Obek (Turkey), M Krengli (Italy)
Management of synchronous mCSPCa in the new era of 2nd generation of hormone therapy
F Guedea (Spain), K Oualla (Morocco), D Geara (UAE)
New generation of hormone therapy and chemotherapy: role and sequence in mCRPCa?
L Popovic (Serbia), P Hurmuz (Turkey), K Debbi (France)
Management of BRCA mutated patients: from labs to patients
D Mukherji (UAE), B El Khannoussi (Morocco), N Radosevic (France)
16:00-16:30:
Coffee break
MAIN ROOM
Moderators
E Ozyar (Turkey)
By A Hassan Abdelaziz (Egypt)
17:00-18:00 :
MAIN ROOM
Moderators
S Turkan (Turkey), Y Belkacemi (France)
By E Merdan Fayda (Turkey)
MEET THE EXPERT DINNER (Sponsored by ELEKTA)
Moderators
M AL-Foheidi (SA) - A Bounedjar (Algeria) - J Malicki (Poland-RPOR)
MAIN ROOM
08:30 :
Locally Advanced Breast Cancer (adjuvant and neoadjuvant) and endocrine therapy for young patients with breast cancer
A Awada (Belgium), J Gligorov (France)
09:15:
Locally Advanced Cervix Cancer
C Chargari (France), D Tesanovic (Serbia)
09:45:
Local and systemic therapy for High risk Prostate Cancer
F Geara (UAE), D Murkherji (UAE)
10:15:
Metastatic Castration Sensitive and Resistant Prostate Cancer
L Popovic (Serbia), K Oualla (Morocco)
10:45:
Closing remarks
ALL
10:45- 11:00:
Coffee breack
11:00-11:30:
MAIN ROOM
By T Wilson (Switzerland)
11:30:
MAIN ROOM
Moderators
E Ozyar (Turkey) - O Ivanov (Serbia) - N Berrada (Morocco)
Mechanism of PARP1/TCF7L2 axis mediated aerobic glycolysis in regulating the metastasis of triple-negative BC
Q Lei (China)
Late toxicity and cosmetic outcome of the ultra-hypofractionated radiotherapy of breast cancer
N Aničić (Serbia)
11:50- 12:00:
Factors associated with acute toxicity of moderately hypofractioned ratherapy in breast cancer: preliminary results of a prospective cohort study
MB Ba (Senegal)
12:00- 12:10:
When an external fixator is used in cervical cancer brachytherapy, can packing be avoided? The rationale of vaginal gauze packing on the rectum and bladder
U Diremsizoglu (Turkey)
Cervical cancer in ederly women: patterns of care in a radiotherapy department in a country with high prevalence
W Hassani (Morocco)
Evaluation of the efficacy and safety of paclitaxel, carboplatin and bevacizumab combination followed by maintenance bevacizumab therapy in recurrent, persistent or metastatic uterine cervical cancer
H Idir (Algeria)
The Turkish Validation of the Expanded Prostate Cancer Index Composite (EPIC) in Prostate Cancer Patients.
B. Tilky (Turkey)
Sexuality and Prostate Cancer
S Nejjari (Morocco), M Alem (Morocco)
Long-term results of cervical cancer patients < 45 Years. A tertiary-center experience
E Demir (Turkey)
Online Adaptive Stereotactic Body Radiotherapy with MR Guidance in the treatment of prostate cancer patients. A Hacettepe University Study
T.Z Mustafayev (Turkey), S Mutaf (Turkey)
Closing remarks
Y Belkacemi (France), A Bounedjar (Algeria), J Gligorov (France), R Samlali (Morocco), S Turkan (Turkey)